SG169351A1 - Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo - Google Patents
Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoInfo
- Publication number
- SG169351A1 SG169351A1 SG201100553-5A SG2011005535A SG169351A1 SG 169351 A1 SG169351 A1 SG 169351A1 SG 2011005535 A SG2011005535 A SG 2011005535A SG 169351 A1 SG169351 A1 SG 169351A1
- Authority
- SG
- Singapore
- Prior art keywords
- fusion protein
- vivo
- fragment
- life
- human erythropoietin
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 9
- 108020001507 fusion proteins Proteins 0.000 title abstract 9
- 238000001727 in vivo Methods 0.000 title abstract 4
- 230000000913 erythropoietic effect Effects 0.000 title abstract 2
- 230000002035 prolonged effect Effects 0.000 title abstract 2
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 abstract 5
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 abstract 5
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 4
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 4
- 102000044890 human EPO Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 108060003951 Immunoglobulin Proteins 0.000 abstract 3
- 102000018358 immunoglobulin Human genes 0.000 abstract 3
- 102000003951 Erythropoietin Human genes 0.000 abstract 2
- 108090000394 Erythropoietin Proteins 0.000 abstract 2
- 229940105423 erythropoietin Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 230000010437 erythropoiesis Effects 0.000 abstract 1
- 230000009851 immunogenic response Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/340,661 US7625564B2 (en) | 2006-01-27 | 2006-01-27 | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG169351A1 true SG169351A1 (en) | 2011-03-30 |
Family
ID=38308802
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201404308RA SG10201404308RA (en) | 2006-01-27 | 2007-01-25 | Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| SG201100553-5A SG169351A1 (en) | 2006-01-27 | 2007-01-25 | Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201404308RA SG10201404308RA (en) | 2006-01-27 | 2007-01-25 | Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
Country Status (21)
| Country | Link |
|---|---|
| US (8) | US7625564B2 (ko) |
| EP (2) | EP2450373B1 (ko) |
| JP (3) | JP5222153B2 (ko) |
| KR (2) | KR101235124B1 (ko) |
| CN (3) | CN102816242B (ko) |
| AU (1) | AU2007209722B2 (ko) |
| BR (1) | BRPI0706742C1 (ko) |
| CA (1) | CA2650072C (ko) |
| DK (2) | DK1994157T3 (ko) |
| ES (2) | ES2539759T3 (ko) |
| HK (2) | HK1125673A1 (ko) |
| IL (1) | IL192801A (ko) |
| MX (1) | MX2008009322A (ko) |
| NZ (1) | NZ569702A (ko) |
| PL (2) | PL2450373T3 (ko) |
| PT (2) | PT1994157E (ko) |
| RU (1) | RU2433181C2 (ko) |
| SG (2) | SG10201404308RA (ko) |
| TW (1) | TWI454482B (ko) |
| WO (1) | WO2007085084A1 (ko) |
| ZA (1) | ZA200805920B (ko) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2365023T3 (es) * | 2004-04-21 | 2011-09-20 | Enobia Pharma Inc. | Conjugados de administración ósea y método de uso de los mismos para dirigir proteínas a hueso. |
| US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
| US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| JP4356902B2 (ja) * | 2006-12-28 | 2009-11-04 | 信広 益子 | 歯ブラシ |
| CA2720628A1 (en) * | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Fusion proteins having mutated immunoglobulin hinge region |
| WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
| NZ594638A (en) | 2009-02-24 | 2013-03-28 | Alexion Pharma Inc | Antibodies containing therapeutic tpo/epo mimetic peptides for treatment of thrombocytopenia type conditions |
| US20110016548A1 (en) * | 2009-07-16 | 2011-01-20 | University Of Southern California | Control of endogenous dnmt1 gene expression by exogenous binary regulatory systems |
| WO2011134084A1 (en) | 2010-04-30 | 2011-11-03 | Enobia Pharma Inc. | Methods, compositions, and kits for the treatment of matrix mineralization disorders |
| CN102260343A (zh) | 2010-05-25 | 2011-11-30 | 健能隆医药技术（上海）有限公司 | 重组人g-csf二聚体在治疗神经损伤疾病中的用途 |
| WO2012088608A1 (en) | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
| MX356433B (es) * | 2011-06-28 | 2018-05-29 | Inhibrx Lp | Polipéptidos de fusión con domino de proteína ácida del suero, y métodos de uso de los mismos. |
| DK2726092T3 (da) | 2011-06-28 | 2019-09-30 | Inhibrx Lp | Serpin-fusionspolypeptider og fremgangsmåder til anvendelse deraf |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| JP5947891B2 (ja) | 2011-07-25 | 2016-07-06 | ジェネロン（シャンハイ）コーポレイション リミテッドＧｅｎｅｒｏｎ （Ｓｈａｎｇｈａｉ） Ｃｏｒｐｏｒａｔｉｏｎ Ｌｔｄ． | 神経変性疾患を治療する医薬品の製造におけるｇ−ｃｓｆ二量体の応用 |
| EP2561888A1 (en) * | 2011-08-23 | 2013-02-27 | Deutsches Krebsforschungszentrum | Protein comprising NC-1 for treating angiogenesis-related diseases |
| WO2013027191A1 (en) * | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
| KR101183615B1 (ko) * | 2011-12-28 | 2012-09-17 | 재단법인 경기과학기술진흥원 | Ｗｎｔ에 결합하는 신규한 재조합 단백질 |
| JP5836402B2 (ja) * | 2012-01-25 | 2015-12-24 | Ｓｂｉファーマ株式会社 | 腫瘍診断剤 |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| AU2013311777B2 (en) * | 2012-09-07 | 2018-02-01 | Sanofi | Fusion proteins for treating a metabolic syndrome |
| WO2014093387A1 (en) * | 2012-12-10 | 2014-06-19 | Kindred Biosciences, Inc. | Vegf receptor fusion proteins for veterinary use |
| AR096890A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn |
| AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
| RU2563175C1 (ru) * | 2014-06-03 | 2015-09-20 | государственное бюджетное образовательное учреждение высшего профессионального образования "Тюменская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ТюмГМА Минздрава России) | Способ стимуляции эритропоэза в предоперационном периоде |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| EP3194429A4 (en) * | 2014-09-18 | 2018-06-13 | Askgene Pharma, Inc. | Novel feline erythropoietin receptor agonists |
| KR20240045379A (ko) | 2014-12-05 | 2024-04-05 | 알렉시온 파마슈티칼스, 인코포레이티드 | 재조합 알칼리성 포스파타제를 이용한 발작 치료 |
| RU2673548C1 (ru) * | 2015-01-09 | 2018-11-28 | Генексин, Инк. | Способ лечения анемии с применением композиции ЕРО длительного действия |
| EP3250227A2 (en) | 2015-01-28 | 2017-12-06 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| WO2016178087A1 (en) | 2015-05-04 | 2016-11-10 | Biosourcing Sa | Transgenic production of chorionic gonadotropin |
| JP2018515073A (ja) | 2015-05-04 | 2018-06-14 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ | Ｆｃ融合タンパク質のトランスジェニック産生 |
| EP3337894A1 (en) | 2015-08-17 | 2018-06-27 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
| WO2017058822A1 (en) | 2015-09-28 | 2017-04-06 | Alexion Pharmaceuticals, Inc. | Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia |
| CN105111315B (zh) * | 2015-09-29 | 2018-05-22 | 海南医学院 | MIP3α-Fc融合蛋白及其用途 |
| ES2941968T3 (es) | 2015-10-01 | 2023-05-29 | The Whitehead Institute For Biomedical Res | Marcaje de anticuerpos |
| KR101847169B1 (ko) * | 2015-10-07 | 2018-04-09 | 주식회사 녹십자 | 지속형 에리트로포이에틴 함유 조성물 |
| JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
| JP2018538271A (ja) * | 2015-11-16 | 2018-12-27 | ユビプロテイン， コーポレーションＵｂｉｐｒｏｔｅｉｎ， Ｃｏｒｐ． | タンパク質の半減期延長方法 |
| EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN |
| EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS |
| CN109152820A (zh) | 2016-04-01 | 2019-01-04 | 阿雷克森制药公司 | 用碱性磷酸酶治疗肌肉无力 |
| WO2017214130A1 (en) | 2016-06-06 | 2017-12-14 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
| US11116821B2 (en) | 2016-08-18 | 2021-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
| US20200078470A1 (en) * | 2016-12-05 | 2020-03-12 | Hanmi Pharm. Co., Ltd. | Conjugate with attenuated immune response |
| EP3600383A4 (en) | 2017-03-31 | 2020-10-28 | Alexion Pharmaceuticals, Inc. | METHODS FOR TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS |
| WO2018203582A1 (ko) * | 2017-05-05 | 2018-11-08 | 주식회사 유비프로틴 | 단백질 반감기를 증가시키는 방법 |
| CN110078817B (zh) * | 2018-01-26 | 2021-02-19 | 重庆精准生物技术有限公司 | 一种改良的铰链区及其在构建car骨架中的应用 |
| WO2019190752A1 (en) | 2018-03-30 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
| WO2020053661A1 (en) | 2018-09-13 | 2020-03-19 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Methods of purifying antibodies from the milk of transgenic non-human mammals comprising the use of chitosan |
| RU2696864C1 (ru) * | 2018-09-24 | 2019-08-07 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики нарушений микроциркуляции в почках асиалированным эритропоэтином в эксперименте |
| RU2678768C1 (ru) * | 2018-09-25 | 2019-02-01 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики ишемически-реперфузионных повреждений почек карбамилированным дарбэпоэтином в эксперименте |
| CN113493519B (zh) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
| US20230357341A1 (en) * | 2020-06-10 | 2023-11-09 | Bica Therapeutics Inc. | Fusion protein containing erythropoietin polypeptide |
| US20230265407A1 (en) * | 2020-07-02 | 2023-08-24 | Northwestern University | Human recombinant ace2-fc mutants that decouple anti-sars-cov-2 activity from cardiovascular effects |
| CN111704676A (zh) * | 2020-07-17 | 2020-09-25 | 上海延立药业有限公司 | 一种长效重组促红细胞生成素及其制备方法和应用 |
| KR102450007B1 (ko) * | 2020-10-16 | 2022-10-04 | 주식회사 아이엠바이오로직스 | IgM 영역을 이용한 융합단백질 플랫폼 |
| BR112023016048A2 (pt) | 2021-02-12 | 2023-11-14 | Alexion Pharma Inc | Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US7253264B1 (en) * | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| DK0464533T3 (da) * | 1990-06-28 | 1999-04-26 | Gen Hospital Corp | Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| ITFI940106A1 (it) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
| DE69534265T2 (de) * | 1994-12-12 | 2006-05-04 | Beth Israel Deaconess Medical Center, Inc., Boston | Chimäre zytokine und ihre verwendung |
| US6096871A (en) * | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US7696338B2 (en) * | 1995-10-30 | 2010-04-13 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin fusion proteins and means for expression thereof |
| US6936439B2 (en) * | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| AU8182298A (en) | 1997-07-10 | 1999-02-08 | Beth Israel Deaconess Medical Center | Recombinant erythropoietin / immunoglobulin fusion proteins |
| US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| WO1999058662A1 (fr) | 1998-05-14 | 1999-11-18 | Merck Patent Gmbh | Proteine fusionnee |
| ES2273497T3 (es) | 1998-06-15 | 2007-05-01 | Gtc Biotherapeutics, Inc. | Proteina de fusion de la albumina serica humana de eritropoyetina analoga. |
| US20050181482A1 (en) | 2004-02-12 | 2005-08-18 | Meade Harry M. | Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| ATE407697T1 (de) | 1999-07-13 | 2008-09-15 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| WO2001030320A1 (en) | 1999-10-22 | 2001-05-03 | Amgen Inc. | Biodegradable microparticles with novel erythropoietin stimulating protein |
| WO2001036489A2 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gmbh | Erythropoietin forms with improved properties |
| US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| US6808902B1 (en) * | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| US6586398B1 (en) * | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| ATE395357T1 (de) | 2000-04-21 | 2008-05-15 | Amgen Inc | Verfahren und zusammensetzungen zur vermeidung und behandlung von anämie |
| AU2002222740A1 (en) | 2000-12-11 | 2002-06-24 | Cheil Jedang Corporation | Fusion protein having the enhanced in vivo activity of erythropoietin |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP2316951A1 (en) * | 2001-01-17 | 2011-05-04 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| PT1366067E (pt) | 2001-03-07 | 2012-11-29 | Merck Patent Gmbh | Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido |
| US6992174B2 (en) * | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| US6797493B2 (en) * | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
| KR100467750B1 (ko) | 2001-11-29 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
| KR100467751B1 (ko) | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
| JP2005526769A (ja) * | 2002-03-15 | 2005-09-08 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 治療剤を全身搬送するための中央気道投与 |
| US20040063912A1 (en) * | 2002-03-15 | 2004-04-01 | The Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
| DE10227606B3 (de) | 2002-06-20 | 2004-01-22 | Bionethos Holding Gmbh | Verwendung von Thrombopoietin zur Kultivierung von Hepatozyten |
| WO2004004798A2 (en) | 2002-07-03 | 2004-01-15 | The Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
| WO2004042017A2 (en) * | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| SI1639011T1 (sl) * | 2003-06-30 | 2009-04-30 | Domantis Ltd | Pegilirana protitelesa z enojno domeno (dAb) |
| EP1663306A2 (en) * | 2003-09-05 | 2006-06-07 | Genentech, Inc. | Antibodies with altered effector functions |
| US20060134105A1 (en) * | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| CN1902222A (zh) * | 2003-12-31 | 2007-01-24 | 默克专利有限公司 | 具有改善药物代谢动力学的Fc－促红细胞生成素融合蛋白质 |
| EP1586585A1 (de) * | 2004-04-14 | 2005-10-19 | F. Hoffmann-La Roche Ag | Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung |
| JP2008527981A (ja) | 2005-01-25 | 2008-07-31 | アポロ ライフ サイエンシズ リミテッド | 治療目的および診断目的のためにパラメーターにより選択されたｇｍ−ｃｓｆ、ｉｌ−３、ｉｌ−４、ｉｌ−５、ならびにそのキメラ |
| CA2621705A1 (en) * | 2005-11-24 | 2007-05-31 | Laboratoires Serono S.A. | Erythropoietin polypeptides and uses thereof |
| US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| CA2720628A1 (en) * | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Fusion proteins having mutated immunoglobulin hinge region |
-
2006
- 2006-01-27 US US11/340,661 patent/US7625564B2/en active Active
-
2007
- 2007-01-25 CN CN201210211118.XA patent/CN102816242B/zh active Active
- 2007-01-25 AU AU2007209722A patent/AU2007209722B2/en active Active
- 2007-01-25 EP EP12153232.9A patent/EP2450373B1/en active Active
- 2007-01-25 PT PT77193480T patent/PT1994157E/pt unknown
- 2007-01-25 SG SG10201404308RA patent/SG10201404308RA/en unknown
- 2007-01-25 PL PL12153232T patent/PL2450373T3/pl unknown
- 2007-01-25 KR KR1020087021042A patent/KR101235124B1/ko active IP Right Grant
- 2007-01-25 CN CN2007800004392A patent/CN101321870B/zh active Active
- 2007-01-25 MX MX2008009322A patent/MX2008009322A/es active IP Right Grant
- 2007-01-25 ES ES07719348.0T patent/ES2539759T3/es active Active
- 2007-01-25 EP EP07719348.0A patent/EP1994157B1/en active Active
- 2007-01-25 KR KR1020117031687A patent/KR20120014936A/ko active Search and Examination
- 2007-01-25 US US12/162,320 patent/US10117949B2/en active Active
- 2007-01-25 DK DK07719348.0T patent/DK1994157T3/da active
- 2007-01-25 NZ NZ569702A patent/NZ569702A/en unknown
- 2007-01-25 WO PCT/CA2007/000107 patent/WO2007085084A1/en active Application Filing
- 2007-01-25 PL PL07719348T patent/PL1994157T3/pl unknown
- 2007-01-25 CN CN201210004888.7A patent/CN102516399B/zh active Active
- 2007-01-25 JP JP2008551610A patent/JP5222153B2/ja active Active
- 2007-01-25 SG SG201100553-5A patent/SG169351A1/en unknown
- 2007-01-25 ES ES12153232.9T patent/ES2539778T3/es active Active
- 2007-01-25 DK DK12153232.9T patent/DK2450373T3/da active
- 2007-01-25 RU RU2008134389/10A patent/RU2433181C2/ru active
- 2007-01-25 CA CA2650072A patent/CA2650072C/en active Active
- 2007-01-25 PT PT121532329T patent/PT2450373E/pt unknown
- 2007-01-25 BR BRPI0706742A patent/BRPI0706742C1/pt active IP Right Grant
- 2007-07-20 TW TW096126612A patent/TWI454482B/zh active
-
2008
- 2008-07-08 ZA ZA200805920A patent/ZA200805920B/xx unknown
- 2008-07-14 IL IL192801A patent/IL192801A/en active IP Right Grant
-
2009
- 2009-04-17 HK HK09103538.4A patent/HK1125673A1/xx unknown
- 2009-09-08 US US12/555,743 patent/US8431132B2/en active Active
- 2009-09-08 US US12/555,742 patent/US7964375B2/en active Active
-
2012
- 2012-11-08 HK HK12111281.1A patent/HK1170507A1/xx unknown
- 2012-12-06 JP JP2012267451A patent/JP6103579B2/ja active Active
-
2013
- 2013-04-29 US US13/872,790 patent/US9375487B2/en active Active
-
2015
- 2015-09-14 JP JP2015180997A patent/JP2016006116A/ja active Pending
-
2016
- 2016-06-27 US US15/194,306 patent/US10233223B2/en active Active
-
2018
- 2018-05-29 US US15/992,068 patent/US11279742B2/en active Active
-
2022
- 2022-03-21 US US17/700,251 patent/US20230265143A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG169351A1 (en) | Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo | |
| US20220127623A1 (en) | Fusion proteins having mutated immunoglobulin hinge region | |
| EP1362062A4 (en) | CONCATAMERE IMMUNADHÄSION | |
| RU2006127552A (ru) | Слитые белки il-7 | |
| JP7174149B2 (ja) | ＧＬＰ１－Ｆｃ融合タンパク質及びその複合体 | |
| RU2006127554A (ru) | Fc-эритропоэтин слитый белок с улучшенной фармакокинетикой | |
| EP3892632A1 (en) | Modified product of fc domain of antibody | |
| MY157907A (en) | Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo | |
| KR102334315B1 (ko) | 신규 중간체 제조를 통한 지속형 약물 결합체의 제조 방법 | |
| Mills | Analytical Development and Characterization of the Metal-binding claMP Tag for Generation of Inline Bioconjugates to Enable Targeted Metal Delivery: Evaluation of Tag Placement, Metal Insertion and Retention, and Stability of Ni (II)-claMP-Tagged Protein Variants | |
| TH97398B (th) | โปรตีนเชื่อมต่อของ EPO ของคน -Fc ชนิดรีคอมบิแนนท์ที่มีเวลาครึ่งอายุนานขึ้นและการออกฤทธิ์สร้างเซลเม็ดเลือดเพิ่มขึ้นในกาย |